GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
JR Browna, JA Woyachb, K Patelc, TA Eyred, Cy Cheahe,f, P Ghiag, W Jurczakh, P Abadai, WG Wierdaj, GFPN Presenterk
a Dana-Farber Cancer Institute and Harvard Medical School, Boston, United States
b The Ohio State University Comprehensive Cancer Center, Columbus, United States
c Swedish Cancer Institute, Seattle, United States
d Churchill Cancer Center, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
e Linear Clinical Research, Perth, Australia
f Sir Charles Gairdner Hospital, Perth, Australia
g Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy
h Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
i Loxo@Lilly, Indianapolis, United States
j University of Texas MD Anderson Cancer Center, Houston, United States
k Hospital Israelita Albert Einstein (HIAE), São Paulo, Brazil
Ver másRead
1169
Timeswas read the article
435
Total PDF
734
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 9 | 6 | 5 | 11 |
| 2025 8 | 48 | 36 | 84 |
| 2025 7 | 42 | 28 | 70 |
| 2025 6 | 47 | 17 | 64 |
| 2025 5 | 69 | 11 | 80 |
| 2025 4 | 32 | 12 | 44 |
| 2025 3 | 54 | 8 | 62 |
| 2025 2 | 45 | 16 | 61 |
| 2025 1 | 31 | 25 | 56 |
| 2024 12 | 21 | 18 | 39 |
| 2024 11 | 32 | 18 | 50 |
| 2024 10 | 28 | 19 | 47 |
| 2024 9 | 41 | 18 | 59 |
| 2024 8 | 47 | 20 | 67 |
| 2024 7 | 33 | 24 | 57 |
| 2024 6 | 34 | 20 | 54 |
| 2024 5 | 34 | 35 | 69 |
| 2024 4 | 36 | 21 | 57 |
| 2024 3 | 22 | 14 | 36 |
| 2024 2 | 10 | 12 | 22 |
| 2024 1 | 4 | 4 | 8 |
| 2023 12 | 7 | 26 | 33 |
| 2023 11 | 8 | 19 | 27 |
| 2023 10 | 3 | 9 | 12 |
Show all
